Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
about
Clinical use of whole genome sequencing for Mycobacterium tuberculosisDrug-resistant TB: deadly, costly and in need of a vaccineManagement of multidrug-resistant TB: novel treatments and their expansion to low resource settingsComparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohortStudy of streptomycin-induced ototoxicity: protocol for a longitudinal study.eis Promoter C14G and C15G Mutations Do Not Confer Kanamycin Resistance in Mycobacterium tuberculosis.Adverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia.In vivo efficacy of apramycin in murine infection models.Imported bugs, not beasts: extensively drug-resistant tuberculosis and acute kidney injury.Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis PatientsEvaluation of community-based treatment for drug-resistant tuberculosis in BangladeshPharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of TuberculosisPrinciples for designing future regimens for multidrug-resistant tuberculosis.Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting.A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.Hearing thresholds in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations.The safety and tolerability of the second-line injectable antituberculosis drugs in children.Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease.Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains.Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS.Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.Aminoglycoside-induced hearing deficits – a review of cochlear ototoxicityManagement of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series
P2860
Q26752636-BE32007E-68B9-41A4-BCB5-34EE3D97FA94Q26765385-E6DF61C7-586C-4850-ABF9-3063F27FD606Q26765394-E3F51845-2228-4E27-8E7D-D8345E6E1E38Q27318102-E257E3D5-26F6-4796-ACDF-C55976FBF2B6Q27318765-DA00555F-31C9-4715-8DB2-F66D27B2C635Q30275565-7EBA334D-84C8-40A6-BD73-5A3DACE5BE26Q30829979-03515B93-DB05-4656-9A17-EAFC7BD257C3Q34596853-2B9274BA-2754-4DE0-9229-F255418307FCQ35310567-817EFE65-5597-4ACF-8262-A7F8C1CC1B4FQ35823335-55CCA163-0AB5-4712-91CF-EC2AC02C8AECQ36075986-380B07A0-FE44-4ADE-8856-FA1F5C1DE902Q36479814-EE57EAE8-8492-4858-8975-AF721DCFB70CQ37023099-2C379CBF-E571-421A-9348-CB092D8CDE6AQ37398037-6762C0BB-6FA5-45A1-8ADF-6B50219EAD0FQ37998242-3CAEB018-FC5A-4076-A61B-EF8487FF472CQ38582633-6C0E116D-17B6-4824-BF3D-FA7ED7D43302Q38660046-726CCA0A-8CD0-4B93-923C-7F33B31971D3Q38933875-FE9D11D7-DB49-4E4F-8DC5-5B652764A5F2Q40067743-CED90D6A-7161-4337-826B-10E55984E5E8Q40139987-E68746F9-4C95-4E3F-A090-3B939CCFC0A0Q40306588-B00A1D47-85B9-45D2-9CA6-E25248DB6782Q42278836-AB4A1FC9-C505-4DF9-B564-830184187508Q42714559-335738C5-4E8A-4339-896A-6B04C5FFAE11Q43745618-9F6912CF-F713-4C48-B9DE-56AE5BC4D704Q50315312-7263C4DD-61B8-4B2F-B43A-80F48C1E5F81Q55407610-0191E175-42DC-4C72-A824-45B31DB68370Q56385444-5317A27D-AA86-48D6-A963-F2C72E0D9462Q58741073-C0FE3490-FC73-46F8-9497-7B047590791B
P2860
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Multidrug-resistant tuberculos ...... use and toxicity in practice.
@en
Multidrug-resistant tuberculosis
@nl
type
label
Multidrug-resistant tuberculos ...... use and toxicity in practice.
@en
Multidrug-resistant tuberculosis
@nl
prefLabel
Multidrug-resistant tuberculos ...... use and toxicity in practice.
@en
Multidrug-resistant tuberculosis
@nl
P2093
P2860
P50
P356
P1476
Multidrug-resistant tuberculos ...... use and toxicity in practice.
@en
P2093
Angela Loyse
Ann Sturdy
Anna Goodman
Laurence John
Marc Lipman
Marie O'Donoghue
Martin J Dedicoat
Ricardo J José
P2860
P304
P356
10.1093/JAC/DKR221
P407
P577
2011-06-03T00:00:00Z